The incidence of ILD in our study was 4.4%, which is higher than the incidence in the Japanese subgroup of patients in the phase III OAK study (1.8%) (23), but lower than in a previous report with the PD-1 inhibitor pembrolizumab in Japanese patients with NSCLC (22.2%) (24). Here, PDCD1 is linked to interstitial lung disease.